BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 6277024)

  • 21. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients.
    Stendahl M; Rydén L; Nordenskjöld B; Jönsson PE; Landberg G; Jirström K
    Clin Cancer Res; 2006 Aug; 12(15):4614-8. PubMed ID: 16899609
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).
    Schmid P; Untch M; Wallwiener D; Kossé V; Bondar G; Vassiljev L; Tarutinov V; Kienle E; Lüftner D; Possinger K;
    Anticancer Res; 2002; 22(4):2325-32. PubMed ID: 12174922
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
    Mariotto AB; Feuer EJ; Harlan LC; Abrams J
    J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of operative devascularization on estrogen and progesterone receptor levels in breast cancer specimens.
    Teicher I; Tinker MA; Auguste LJ; Laufer H; Stein TA; Wise L
    Surgery; 1985 Oct; 98(4):784-91. PubMed ID: 4049250
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
    Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
    Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Prospective randomized trial on the efficacy of adjuvant endocrine therapy for ER-positive breast cancer patients after radical mastectomy].
    Jiang Z; Song S; Liu X
    Zhonghua Zhong Liu Za Zhi; 2001 Sep; 23(5):420-2. PubMed ID: 11810777
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy.
    Buchholz TA; Hill BS; Tucker SL; Frye DK; Kuerer HM; Buzdar AU; McNeese MD; Singletary SE; Ueno NT; Pusztai L; Valero V; Hortobagyi GN
    Cancer J; 2001; 7(5):413-20. PubMed ID: 11693900
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
    Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
    J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy.
    Truong PT; Olivotto IA; Kader HA; Panades M; Speers CH; Berthelet E
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1337-47. PubMed ID: 15817335
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The importance of steroid receptors for the prognosis and hormone treatment of breast cancer patients: a retrospective study in Southeastern Netherlands].
    Voogd AC; Crommelin MA; Repelaer van Driel OJ; Tutein Nolthenius-Puylaert MC; Vreugdenhil G; Coebergh JW
    Ned Tijdschr Geneeskd; 1998 Aug; 142(31):1772-8. PubMed ID: 9856143
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
    Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
    Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A randomized study of adjuvant treatments for operable breast cancer patients stratified by estrogen receptor and menopausal status].
    Nomura Y; Tsutsui S; Murakami S; Takenaka Y
    Gan To Kagaku Ryoho; 1999 Apr; 26(5):643-9. PubMed ID: 10234295
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved survival for women with stage I breast cancer in south-east Sweden: a comparison between two time periods before and after increased use of adjuvant systemic therapy.
    Johansson P; Fohlin H; Arnesson LG; Dufmats M; Nordenskjöld K; Nordenskjöld B; Stål O;
    Acta Oncol; 2009; 48(4):504-13. PubMed ID: 19235568
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sites of failure in breast cancer patients with extracapsular invasion of axillary lymph node metastases. No need for axillary irradiation?!
    Gruber G; Menzi S; Forster A; Berclaz G; Altermatt HJ; Greiner RH
    Strahlenther Onkol; 2005 Sep; 181(9):574-9. PubMed ID: 16170484
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.
    Bartlett JM; Ellis IO; Dowsett M; Mallon EA; Cameron DA; Johnston S; Hall E; A'Hern R; Peckitt C; Bliss JM; Johnson L; Barrett-Lee P; Ellis P
    J Clin Oncol; 2007 Oct; 25(28):4423-30. PubMed ID: 17906205
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association between steroid hormone receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer.
    Allegra JC; Lippman ME; Thompson EB; Simon R; Barlock A; Green L; Huff KK; Do HM; Aitken SC; Warren R
    Cancer Treat Rep; 1978 Sep; 62(9):1281-6. PubMed ID: 688273
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer.
    Lippman ME; Allegra JC; Thompson EB; Simon R; Barlock A; Green L; Huff KK; Do HM; Aitken SC; Warren R
    N Engl J Med; 1978 Jun; 298(22):1223-8. PubMed ID: 651963
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Which patients with estrogen receptor-positive early breast cancer should be treated with adjuvant chemotherapy?
    Chiuri VE; Lorusso V
    Oncology; 2009; 77 Suppl 1():18-22. PubMed ID: 20130428
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estrogen receptor assay in primary breast cancer and early recurrence of the disease.
    Maynard PV; Blamey RW; Elston CW; Haybittle JL; Griffiths K
    Cancer Res; 1978 Nov; 38(11 Pt 2):4292-5. PubMed ID: 698968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.